MOSCOW, September 13. / TASS /. Moscow is taking an active part in testing the anticoid immunoglobulin developed by the Natsimbio immunobiological company, for example, the capital donated 7.5 tons of plasma from coronavirus patients for research. This was announced in an interview with TASS by the deputy mayor of the capital for social development Anastasia Rakova.
“We are working to develop such a new drug as a specific antikoid immunoglobulin. To create it, not just the plasma of those who have been ill is used, but a specific immunoglobulin is released, and this drug is supplied and used [in treatment]. Unlike plasma, it is safer and easier to use. To date, the third phase of trials of this drug has begun, “Rakova said.
According to her, Moscow gave Natsimbio 7.5 tons of plasma from those who had been ill with covid and received 900 vials of immunoglobulin, which is now actively used, and specialists record the results in covid hospitals.
The deputy mayor noted that the capital is trying to monitor how coronavirus is being treated around the world, and to implement the latest developments, for this, its own clinical committee has even been created. According to Rakova, the city has already begun to use monoclonal antibodies, which are also widely used in the world. To date, the treatment is actively turning to the blood plasma of those who have been ill – more than 17 thousand patients in the capital have already received such treatment.
“For them (those who have had coronavirus – TASS note), a decision has been made to conduct a special in-depth clinical examination, which implies an expanded range of studies. some deviations in health indicators were identified, then they undergo more in-depth studies already in polyclinics, sign up for a consultation with specialists and receive appropriate treatment. Approximately 40 thousand people have already used this option and underwent appropriate studies, “Rakova added.
In early April, the Ministry of Health of the Russian Federation registered the world's first specific immunoglobulin to coronavirus based on the blood plasma of people who had been ill. It is assumed that after the completion of the II and III phases of clinical trials, the drug will be used to treat moderate and severe forms of the disease.
